Scilex Holding Co entered into ACEA-PHOE SAA with Phoenix Asia Holdings Limited valued at $1,000,000,000.00 (effective 2026-05-04).
“On May 4, 2026, ACEA Therapeutics, Inc. (“ACEA Thera”), an indirect minority owned subsidiary of Scilex Holding Company (the “Company”), entered into a Stock Acquisition Agreement (the “ACEA-PHOE SAA”) with Phoenix Asia Holdings Limited, a company organized under the laws of the Cayman Islands (“Phoenix Asia”), and ACEA Pharma, Inc., a wholly owned subsidiary of ACEA Thera and an exempted company incorporated with limited liability in the Cayman Islands (“ACEA Pharma”), pursuant to which ACEA Thera agreed to transfer and sell, and Phoenix Asia agreed to purchase, 100% of the issued and outstanding shares of common stock of ACEA Pharma in exchange for the delivery to ACEA Thera of 100,000,000 newly-issued ordinary shares at $10.00 per share, par value $0.00001 per share, of Phoenix Asia (the “Stock Acquisition”), the value of which was as agreed by the parties to be $1,000,000,000.00.”
Material Agreements
Scilex Holding Co entered into Term Sheet with Datavault AI Inc. valued at $120,000,000 (effective 2026-04-26).
“On April 26, 2026, Scilex Holding Company (the “Company”) and Datavault AI Inc. (“Datavault”) and entered into a binding term sheet (the “Term Sheet”), which sets forth the principal terms and conditions of a proposed cash contribution and revenue participation arrangement between the Company and Datavault (the “Proposed Transaction”).”
Material Agreements
Scilex Holding Co entered into Warrant Agreement with Oramed Pharmaceuticals Inc. (effective 2026-02-19).
“On February 19, 2026, Scilex Holding Company (the “ Company ”) entered into a Warrant Agreement (the “ Warrant Agreement ”) with Oramed Pharmaceuticals Inc. (“ Oramed ”).”
Governance Changes
Scilex Holding Co: Filed Certificate of Elimination to eliminate Series 1 Mandatory Exchangeable Preferred Stock designation, causing such shares to become undesignated preferred stock (effective 2026-02-03).
“On February 3, 2026, in connection with the Dividend Revocation, the Company filed a Certificate of Elimination of Series 1 Mandatory Exchangeable Preferred Stock (the “Certificate of Elimination”) with the Secretary of State of the State of Delaware. The Certificate of Elimination, which became effective immediately upon filing, eliminated the previously designated 5,000,000 shares of Series 1 Mandatory Exchangeable Preferred Stock and caused such shares to resume their status as undesignated shares of preferred stock of the Company.”
Material Agreements
Scilex Holding Co entered into common stock purchase agreement with Quantum Scan Holdings, Inc. valued at approximately $27.5 million (effective 2026-01-29).
“The Company and Q Scan entered into a common stock purchase agreement, dated January 29, 2026, with Q Scan (the “Stock Purchase Agreement”). Pursuant to the Stock Purchase Agreement, Q Scan agreed to sell to the Company, and the Company agreed to purchase from Q Scan, an aggregate of 193,021,436 shares of Common Stock (the “Stock Purchase”) for an aggregate purchase price of approximately $27.5 million.”
Material Agreements
Scilex Holding Co entered into Convertible Promissory Note with Quantum Scan Holdings, Inc. valued at $20 million (effective 2026-01-29).
“Scilex Holding Company (the “Company”) entered into a Convertible Promissory Note, dated January 29, 2026 (the “Note”), with Quantum Scan Holdings, Inc. (“Q Scan”). Pursuant to the Note, the Company loaned Q Scan an aggregate of $20 million.”
Debt Financings
Scilex Holding Co incurred loan of up to $100 million with The St. James Bank & Trust Company Ltd. at the 12-month Secured Overnight Financing Rate maturing the eighth anniversary of the closing date of the first tranche of the Loan.
“On December 16, 2025, SCLX Stock Acquisition JV LLC (“SCLX JV”), a wholly-owned subsidiary of Scilex Holding Company (the “Company”), entered into a Non-Recourse Loan and Securities Pledge Agreement (the “Loan Agreement”) with The St. James Bank & Trust Company Ltd., a corporation existing under the laws of the Bahamas (the “Lender”), pursuant to which the Lender agreed to loan SCLX JV an aggregate principal amount of up to $100 million in one or more tranches (the “Loan”).”
Debt Financings
Scilex Holding Co incurred loan of up to $50 million with The St. James Bank & Trust Company Ltd. at 12-month Secured Overnight Financing Rate plus 2.0% per annum maturing fourth anniversary of the closing date of the first tranche of the Loan.
“pursuant to which the Lender agreed to loan the Company an aggregate principal amount of up to $50 million in one or more tranches”
M&A Transactions
Scilex Holding Co completed an acquisition involving Datavault AI Inc. for $150 million in Bitcoin (closed 2025-11-25).
“(the “Pre-Funded Warrant”) to purchase 263,914,094 shares of Datavault Common Stock in a subsequent closing (the “Subsequent Closing”), for an aggregate purchase price of $150 million in Bitcoin (“BTC”) (based on the spot exchange rate for BTC as published by Coinbase.com at 8:00 p.m. (New York City time) on the trading day immediately prior to the date of the”
M&A Transactions
Scilex Holding Co completed a disposition involving Biconomy PTE.LTD for $16.00 per share (closed 2025-09-25).
“Common Stock held by the Company and (ii) 11,945,151 shares of Semnur Common Stock held by Scilex, Inc. The Biconomy Resale SPA Shares are being sold for a purchase price of $16.00 per share (the “Purchase Price”), payable in Bitcoin blockchain (“Bitcoin”), with such amount of Bitcoin equal to the quotient of (A) Biconomy’s aggregate Purchase Price divided”
David Lemus resigned as Director at Scilex Holding Co.
“On November 27, 2024, David Lemus notified the Board of Directors (the “ Board ”) of Scilex Holding Company (the “ Company ”) that he was resigning from the Board, all committees of the Board and any director or officer position held with any subsidiary of the Company, effective as of November 27, 2024, for personal and professional reasons.”
Annu Navani, M.D. was appointed as Class II director at Scilex Holding Co.
“On July 21, 2024, Scilex Holding Company (the “ Company ”) appointed Annu Navani, M.D. as a Class II director of the Company and as a member of the Commercialization and Transaction Committee of the Board of Directors of the Company (the “ Board ”).”
Material Agreements
Scilex Holding Co entered into Purchase Agreement with the investor named therein valued at $15,000,000 (effective 2024-04-23).
“On April 23, 2024, Scilex Holding Company (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with the investor named therein, pursuant to which the Company agreed to sell and issue, in a registered direct offering (the “Offering”): (i) an aggregate of 15,000,000 shares of its common stock (the “Shares”), and (ii) common warrants to purchase up to 15,000,000 shares of its common stock”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.